Pennington, NJ, United States of America

Robert Zahler

USPTO Granted Patents = 74 (Patent Applications = 25)

CIPO Patents = 12 (Patent Applications = 20)

EPO Patents = 17 (Patent Applications = 30)

Average Co-Inventor Count = 3.2

ph-index = 14

Forward Citations = 530(Granted Patents)

Forward Citations (Not Self Cited) = 450(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Princeton, NJ (US) (1985 - 1998)
Pennington, NJ (US) (1993 - 2023)

Company Filing History:

29 out of 1,624

E. R. Squibb Sons, Inc.

Agios Pharmaceuticals, Inc.

patents

4. 3 out of 3,684

Bristol-myers Squibb Compnay

patents

5. 3 out of 17

Tetraphase Pharmaceuticals, Inc.

patents

6. 2 out of 15

Advinus Therapeutics Private Limited

patents

7. 2 out of 118

Osi Pharmaceuticals, Inc.

patents

8. 2 out of 15

Morphic Therapeutic, Inc.

patents

9. 2 out of 21

Servier Pharmaceuticals LLC

patents

10. 1 out of 48

Piramal Enterprises Limited

patents

11. 1 out of 806

National University of Singapore

patents

12. 1 out of 2,893

The General Hospital Corporation

patents

13. 1 out of 123

Institut National De La Recherche Scientifique

Years Active: 1985-2025

Loading Chart...

Areas of Expertise:

Therapeutically Active Compounds

Integrin Inhibition

Fumigillol Compounds

Tricyclic Sulphonamide

Lysophosphatidylcholine Scaffolds

Antibiotic Tolerance Inhibitors

Amino Pyrimidine Anticancer Compounds

Beta Lactam Compounds

Purinyl Salts

Protease Inhibitors

Spirocyclic Compounds

Kinase Inhibitors

74 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12433895 - Therapeutically active compounds and their methods of use (2025-10-07),

2. 11844758 - Therapeutically active compounds and their methods of use (2023-12-19),

3. 11370773 - Inhibiting human integrin (alpha-4) (beta-7) (2022-06-28),

4. 11104661 - Inhibiting human integrin (α-4) (β-7) (2021-08-31),

5. 10946023 - Therapeutically active compounds and their methods of use (2021-03-16),

6. 10220015 - Fumigillol compounds and methods of making and using same (2019-03-05),

7. 10175256 - Compositions and methods utilizing lysophosphatidylcholine scaffolds (2019-01-08),

8. 10174009 - Tricyclic sulphonamide compounds and methods of making and using same (2019-01-08),

9. 10172864 - Therapeutically active compounds and their methods of use (2019-01-08),

10. 10028961 - Therapeutically active compounds and their methods of use (2018-07-24),

11. 10023561 - Fumagillol heterocyclic compounds and methods of making and using same (2018-07-17),

12. 9944613 - Fumagillol spirocyclic compounds and fused bicyclic compounds and methods of making and using same (2018-04-17),

13. 9895339 - Fumigillol compounds and methods of making and using same (2018-02-20),

14. 9868717 - Tricyclic sulphonamide compounds and methods of making and using same (2018-01-16),

15. 9839623 - Tricyclic compounds and methods of making and using same (2017-12-12),

Title: The Inventor Profile of Robert Zahler

Introduction: Robert Zahler is a distinguished inventor based in Pennington, NJ (US) known for his groundbreaking contributions to various fields.

Latest Patents: Robert Zahler holds several patents in the areas of technology and engineering, showcasing his innovative mindset and problem-solving abilities.

Career Highlights: With a career spanning over two decades, Robert Zahler has worked on numerous projects that have revolutionized industries and improved existing technologies.

Collaborations: Throughout his career, Robert Zahler has collaborated with leading experts in the field, fostering a culture of innovation and knowledge-sharing.

Conclusion: Robert Zahler's passion for innovation and his dedication to pushing the boundaries of what is possible make him a standout figure in the world of inventors.

This text is generated by artificial intelligence and may not be accurate.